Relispray Antifungal Powder
NDC Package 46063-552-12

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Relispray Antifungal Powder is wash the affected area and dry thoroughlyshake can well and apply a thin layer over the affected area twice daily (morning and night)supervise children in the use of this productfor athlete's foot:pay special attention to spaces between the toeswear well-fitting, ventilated shoeschange shoes and socks at least once dailyfor athlete's foot and ringworm: use daily for 4 weeksfor jock itch, use daily for 2 weeksif condition persists longer, consult a doctorthis product is not effective on the scalp or nails. Marketed by Midas-care Pharmaceuticals Pvt. Ltd., this product is identified by NDC 46063-552 and is authorized under FDA application M005.

Identification & Billing

NDC Package Code
46063-552-12
Package Description
128 g in 1 CAN
Product Code
46063-552
11-Digit Billing Format
46063055212
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Relispray Antifungal Powder
Dosage Form
-
Usage Information
Wash the affected area and dry thoroughlyshake can well and apply a thin layer over the affected area twice daily (morning and night)supervise children in the use of this productfor athlete's foot:pay special attention to spaces between the toeswear well-fitting, ventilated shoeschange shoes and socks at least once dailyfor athlete's foot and ringworm: use daily for 4 weeksfor jock itch, use daily for 2 weeksif condition persists longer, consult a doctorthis product is not effective on the scalp or nails

Regulatory & Marketing

Labeler Name
Midas-care Pharmaceuticals Pvt. Ltd.
FDA Application #
M005
Marketing Category
OTC MONOGRAPH DRUG -
Start Marketing Date
03-01-2022
Listing Expiration
12-31-2025
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 46063-552-12 identifies a specific commercial package of 128 g in 1 can of Relispray Antifungal Powder, labeled by Midas-care Pharmaceuticals Pvt. Ltd.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Midas-care Pharmaceuticals Pvt. Ltd. on March 01, 2022. The current certification is valid through December 31, 2025.

How is this Midas-care Pharmaceuticals Pvt. Ltd. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 46063055212. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
46063-552-12
11-Digit CMS (5-4-2)
46063-0552-12

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.